For example, PROTAC ARV-110, which uses UPP to degrade the androgen receptor (AR) protein, has demonstrated some efficacy in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC). Here, AR is linked to prostate carcinoma.